Pharmaceutical

AD/PD 2024: TauRx’s HMTM promising despite lacking primary endpoint data

Participants cannot remain blind to their treatment arm due to the properties of TauRx's drug, which causes urinary discoloration.

Mar 9, 2024 - 18:00
AD/PD 2024: TauRx’s HMTM promising despite lacking primary endpoint data
Participants cannot remain blind to their treatment arm due to the properties of TauRx's drug, which causes urinary discoloration.
Read the original article

Tags:

Previous Article

STAT+: Former medical device CEO who sold dummy, plastic parts convicted of fraud

Next Article

AD/PD 2024: exploring cutting-edge therapies for ALS

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

J&J seeks EU approval for new Darzalex multiple myeloma indication

J&J seeks EU approval for new Darzalex multiple myeloma...

Mar 7, 2024

STAT+: Sen. Cassidy wants to put a stop to FDA delays in drug review process

STAT+: Sen. Cassidy wants to put a stop to FDA delays i...

Jun 8, 2023

Pembrolizumab by Merck for Mycosis Fungoides: Likelihoo...

Nov 16, 2023